Filing Flows › GeneDx Holdings (WGS) › Q4 2024
GeneDx Holdings (WGS) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 20, 2025
GeneDx Holdings (WGS) reported revenue of $95.6M for the fourth quarter 2024 (Q4 2024), +67% from a year earlier and +24% from the quarter before. Operating margin was 9.2%, net earnings $5.4M (5.7% of revenue).
GeneDx Holdings, Q4 2024: revenue $95.6M (+67% year over year), operating margin 9.2%, net earnings $5.4M, operating cash flow −$3.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $95.6M | +24% | +67% |
| Gross profit | $66.2M | +38% | +115% |
| Operating profit | $8.8M | — | — |
| Net earnings | $5.4M | — | — |
| Operating cash flow | −$3.2M | — | — |
What changed
Revenue was $95.6M in Q4 2024, up 67% year over year and up 24% from the previous quarter. Patients with third-party insurance was the largest line at 83% of revenue.
Gross margin was 69.2%, up 15.7 points from a year earlier. Operating profit was $8.8M, a 9.2% margin (up 53.9 points year over year). Operating expenses grew 2% against revenue growth of 67%. Net earnings were $5.4M. The effective tax rate was -0.4%.
Operating cash flow was −$3.2M. Non-cash charges added back $5.6M of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items used $17.0M. Capital expenditures of $3.0M exceeded it, leaving free cash flow of −$6.2M.
Questions
What was GeneDx Holdings' revenue in the fourth quarter 2024?
GeneDx Holdings (WGS) reported revenue of $95.6M for the fourth quarter 2024 (Q4 2024), +67% from a year earlier and +24% from the quarter before.
Was GeneDx Holdings profitable in the fourth quarter 2024?
Operating profit was $8.8M (9.2% of revenue) and net earnings $5.4M.
Source: GeneDx Holdings 10-K on SEC EDGAR.